MOTS-c reversed age-related insulin resistance in mice

Has MOTS-c been tested in humans?

No published study has given MOTS-c to humans; the first controlled human trial, a Phase 2a in prediabetes, began recruiting in February 2026 and has not reported ^[5].

The trial, NCT07505745, is a double-blind, placebo-controlled study of 12 weeks of subcutaneous MOTS-c in adults with prediabetes and overweight or obesity. Its primary endpoint is an OGTT-derived insulin sensitivity index, the Matsuda index, and it plans to enroll an estimated 120 participants ^[5].

NCT07505745 is the first study that will show whether the mouse insulin-sensitizing story translates to people, at what dose, and with what side-effect profile. Until it reports, that translation is unknown, not "likely" or "probable."

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, in a region overlapping the 12S rRNA gene, not in nuclear DNA.

That origin is the novel part of the story. Mitochondria, long treated as metabolic hardware, also encode signaling molecules that act elsewhere in the body, and MOTS-c is one of a small family of these "mitochondrial-derived peptides."

Cells produce MOTS-c, it circulates in blood, and its levels change with exercise and age. That much is settled. What happens when synthetic MOTS-c is given to a person is not settled at all.

How does MOTS-c work?

MOTS-c activates AMPK, a central cellular energy sensor, in mouse skeletal muscle ^[1], and later work found a second, more upstream role in the cell nucleus.

The original 2015 paper described a clean story: MOTS-c activates AMPK in skeletal muscle, insulin sensitivity improves, high-fat-diet mice resist obesity, and older mice with age-related insulin resistance partially reverse it ^[1]. The finding is real, specific, and well cited, and nearly every summary article stops there.

Later work found that under metabolic stress, MOTS-c translocates into the nucleus and regulates purine biosynthesis and antioxidant-response gene expression. Most public-facing summaries never mention that shift. The field's understanding of what MOTS-c does inside a cell changed materially within a few years of its discovery, so a confident single-sentence claim such as "MOTS-c activates AMPK, full stop" is outdated shorthand, not the current model.

What did the mouse studies of MOTS-c show?

In mice, systemic MOTS-c prevented diet-induced obesity, reversed age-dependent insulin resistance, and improved physical performance and healthspan in aged animals ^[1]⁠^[2].

The 2015 paper found that systemic MOTS-c treatment prevented diet-induced obesity and reversed age-dependent insulin resistance in mice ^[1]. The 2021 paper found that intermittent MOTS-c dosing improved physical performance and healthspan measures in aged mice. That effect was sex-specific and depended on a particular late-life dosing window, not a broad continuous benefit ^[2].

These are the strongest data that exist for the injected molecule doing anything, and they are entirely rodent. Rodent pharmacology, human biomarker studies, and human genetics answer different questions, and none of these categories can lend another its credibility.

What do human MOTS-c studies show?

Human MOTS-c studies are observational: they show that the body's own MOTS-c responds to exercise and age, and none of them administered the peptide ^[2]⁠^[3]⁠^[4].

A small human component of the 2021 paper found that acute cycling exercise raised endogenous MOTS-c in skeletal muscle and serum in 10 sedentary young men ^[2].

A cohort study of 78 healthy men across three age brackets found that circulating MOTS-c declined with age, while muscle-tissue MOTS-c was paradoxically higher in older groups. Muscle MOTS-c correlated with slow-twitch fiber composition and muscle quality ^[3].

A 16-week supervised exercise RCT in breast cancer survivors raised circulating MOTS-c in non-Hispanic White participants but not in Hispanic participants. Post-exercise MOTS-c correlated with improvements in fat mass, insulin resistance (HOMA-IR), and inflammation markers ^[4].

These are legitimate human data. None of them tested, or could show, what happens when someone injects synthetic peptide.

Does the m.1382A>C longevity variant support MOTS-c injections?

The m.1382A>C variant does not support MOTS-c injections, because it is a naturally occurring sequence variant carried from birth, not adult-onset dosing.

The variant is more common in some long-lived Japanese cohorts. That is a population genetics finding, and it says nothing about the pharmacology of adult-onset subcutaneous dosing. No study has tested whether carrying the variant and injecting the peptide are equivalent.

Treating the variant as supporting evidence for injectable protocols is a category error, however often it gets repeated.

Where do MOTS-c dosing protocols come from?

MOTS-c dosing protocols come from community convention, not from any study: no human dose-finding or pharmacokinetic study of MOTS-c exists.

No published human data establish MOTS-c's half-life in people or its bioavailability by injection route. The doses circulating in forums and vendor materials, commonly a few milligrams injected two to three times weekly and often paired with other peptides, trace to no study in the literature.

Convention does not make those doses automatically dangerous. It means anyone using them is running an uncontrolled single-subject experiment, with no dose-response data behind the number they picked. What research tests in peptide dosing has its own explainer.

What side effects do MOTS-c users report?

MOTS-c users report injection-site pain, burning, and redness, welts and lumps at higher frequency, and gastrointestinal upset at higher doses, all from user reports, not controlled trials.

User reports also raise a theoretical concern about folate-cycle inhibition, with anecdotal advice for people with MTHFR variants to lower doses and add methyl donors. That concern and that advice come from users, not from trials.

Long-term safety in humans is entirely unstudied. Gray-market product purity and identity are also unverified, a problem independent of whether the molecule works. The mitochondrial peptide stack and the MOTS-c and retatrutide combination are reviewed separately.

What is still unknown about MOTS-c?

The Phase 2a trial is the first attempt to answer even the first of these questions about MOTS-c, and its results are not in ^[5]:

• Insulin sensitivity. Whether exogenous MOTS-c improves insulin sensitivity in humans at any dose.
• Performance and aging. Whether MOTS-c has any effect on physical performance or aging biomarkers in people, as opposed to mice.
• Dose. What a safe or effective human dose would look like, since none has been tested.
• Mechanism. Whether the nuclear purine-pathway mechanism or AMPK activation dominates at physiologic versus pharmacologic exposure in human tissue.
• Longevity variant. Whether the m.1382A>C longevity association reflects any mechanism that synthetic-peptide dosing could reproduce.